- Zacks
Alnylam (ALNY) Soars as Heart Disease Drug Study Meets Goals
Alnylam (ALNY) soars as its phase III study, seeking to expand Anvuttra's label to include the treatment of ATTR amyloidosis with cardiomyopathy, achieves primary and all secondary endpoints.
- Investor's Business Daily
Alnylam Skyrockets After Hitting A 'Best-Case Scenario' For Heart Drug
Alnylam stock catapulted Monday after its experimental heart-disease treatment topped expectations in a highly anticipated study.
- Barrons.com
Alnylam Stock Pops on Surprising Results From a Key Heart Disease Drug
The drugmaker says the study met the primary endpoint and demonstrated significant improvements across all secondary endpoints.
